Css LLC Il Takes $222,000 Position in Avid Bioservices, Inc. (NASDAQ:CDMO)

Css LLC Il bought a new position in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,000 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. R Squared Ltd purchased a new position in Avid Bioservices in the fourth quarter valued at approximately $42,000. KLP Kapitalforvaltning AS acquired a new position in shares of Avid Bioservices in the 4th quarter valued at $137,000. Tower Research Capital LLC TRC boosted its holdings in shares of Avid Bioservices by 72.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 12,739 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 5,352 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Avid Bioservices in the 4th quarter valued at $166,000. Finally, HighTower Advisors LLC raised its stake in Avid Bioservices by 23.3% during the 4th quarter. HighTower Advisors LLC now owns 13,861 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 2,620 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Avid Bioservices Price Performance

Shares of CDMO opened at $12.50 on Friday. The company has a debt-to-equity ratio of 3.58, a current ratio of 1.30 and a quick ratio of 0.92. Avid Bioservices, Inc. has a 1-year low of $6.53 and a 1-year high of $12.51. The stock has a market cap of $799.18 million, a PE ratio of -5.23 and a beta of 1.39. The firm has a fifty day moving average price of $12.50 and a 200 day moving average price of $12.40.

About Avid Bioservices

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.